Analysts See $0.06 EPS for DHI Group, Inc. (DHX); Neos Therapeutics, Inc. (NEOS) Had 2 Analysts Last Week

DHI Group, Inc. (NYSE:DHX) Logo

Analysts expect DHI Group, Inc. (NYSE:DHX) to report $0.06 EPS on February, 6.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.06 EPS. DHX’s profit would be $3.17M giving it 8.08 P/E if the $0.06 EPS is correct. After having $0.06 EPS previously, DHI Group, Inc.’s analysts see 0.00% EPS growth. The stock increased 0.52% or $0.01 during the last trading session, reaching $1.94. About 1,132 shares traded. DHI Group, Inc. (NYSE:DHX) has declined 1.18% since January 11, 2018 and is downtrending. It has underperformed by 1.18% the S&P500. Some Historical DHX News: 25/04/2018 – Goldman Sachs clinches crown as ldeal Employer in global financial space; 25/05/2018 – TCS CAPITAL MANAGEMENT, LLC, Affiliates Report Stake In DHI Group; 14/03/2018 – Geneva Rogue Bankers Are Rolling the Dice in More Ways Than One; 25/05/2018 – TCS CAPITAL – COMMUNICATED TO DHI’S CHAIRMAN WILLINGNESS TO BUY DHI IN CASH OR TO BUY POSITION IN CO THROUGH TENDER OFFER/OPEN MARKET TRANSACTIONS; 23/05/2018 – DHI Group, Inc. Sells Hcareers to Virgil Holdings for $16.5 Million; 09/03/2018 – DHI Group Short-Interest Ratio Rises 140% to 18 Days; 26/04/2018 – No Dice for MGM Resorts International — Barron’s Blog; 08/05/2018 – DHI Group 1Q EPS 7c; 17/05/2018 – TIM, A DOMANDA SU DIVIDENDO GENISH DICE CHE VEDE NECESSITA’ Dl INVESTIRE RISORSE IN CAPEX; 29/05/2018 – Element Critical CTO Featured at Bisnow’s DICE: Data Center Investment Conference & Expo East

Among 2 analysts covering Neos Therapeutics (NASDAQ:NEOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neos Therapeutics had 2 analyst reports since August 9, 2018 according to SRatingsIntel. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) earned “Outperform” rating by Wells Fargo on Thursday, August 9. JMP Securities maintained Neos Therapeutics, Inc. (NASDAQ:NEOS) on Monday, November 12 with “Market Outperform” rating. See Neos Therapeutics, Inc. (NASDAQ:NEOS) latest ratings:

12/11/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $22 New Target: $10 Maintain
09/08/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $14 New Target: $11 Maintain

More notable recent Neos Therapeutics, Inc. (NASDAQ:NEOS) news were published by: Nasdaq.com which released: “Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT® Patent Litigation – Nasdaq” on December 26, 2018, also Nasdaq.com with their article: “Airbus 2018 Aircraft Deliveries Up 11% – Nasdaq” published on January 09, 2019, Nasdaq.com published: “Health Care Sector Update for 12/26/2018: GNMK, TEVA, CAPR, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” on December 26, 2018. More interesting news about Neos Therapeutics, Inc. (NASDAQ:NEOS) were released by: Nasdaq.com and their article: “Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock – Nasdaq” published on November 06, 2018 as well as Marketwatch.com‘s news article titled: “Dow soars over 1,000 points as stocks bounce back from Christmas Eve meltdown – MarketWatch” with publication date: December 26, 2018.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $117.73 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

The stock increased 3.04% or $0.07 during the last trading session, reaching $2.37. About 69,532 shares traded. Neos Therapeutics, Inc. (NASDAQ:NEOS) has declined 77.43% since January 11, 2018 and is downtrending. It has underperformed by 77.43% the S&P500. Some Historical NEOS News: 14/03/2018 – Richland Source: Neos’ Wesner teaches dance class at Ashland High School; 09/03/2018 Neos Therapeutics Closes Above 200-Day Average: Technicals; 20/03/2018 – Hindu Bus Line: Two Airbus A320 Neos back in IndiGo fleet; 21/05/2018 – Neos Therapeutics Presenting at UBS Conference Tomorrow; 13/04/2018 – TABLE-Neos 3627.T -2017/18 parent results; 15/05/2018 – Neos Therapeutics Presenting at UBS Conference May 22; 15/04/2018 – MEDIA-All 14 grounded A320 Neos of India’s lndiGo, GoAir back in operation – PTI in Economic Times; 15/03/2018 – Neos Therapeutics 4Q Loss/Shr 49c; 22/04/2018 – DJ Neos Therapeutics Inc, Inst Holders, 1Q 2018 (NEOS); 09/05/2018 – Neos Therapeutics 1Q Loss/Shr 50c

More notable recent DHI Group, Inc. (NYSE:DHX) news were published by: Fool.com which released: “Stock Market Power Rankings: Down Is the New Up – The Motley Fool” on December 16, 2018, also Investorplace.com with their article: “4 Cheap Stocks That Could Head Higher In The Near Future – Investorplace.com” published on September 10, 2018, Seekingalpha.com published: “DHI Group, Inc. (DHX) CEO Art Zeile on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” on August 02, 2018. More interesting news about DHI Group, Inc. (NYSE:DHX) were released by: Zacks.com and their article: “Is DHI Group (DHX) a Great Value Stock Right Now? – Zacks.com” published on December 11, 2018 as well as Seekingalpha.com‘s news article titled: “DHI Group, Inc. (DHX) CEO Art Zeile on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 03, 2018.

DHI Group, Inc. provides specialized Websites focused on select professional communities in the United States and internationally. The company has market cap of $102.61 million. It operates through three divisions: Tech & Clearance, Global Industry Group, and Healthcare. It has a 5.95 P/E ratio. The firm operates Dice that provides job postings of technology and non-technology companies for industries, such as positions for software engineers, big data professionals, systems administrators, database specialists, project managers, and other technology and engineering professionals; and ClearanceJobs, an Internet career network that matches security-cleared professionals with hiring companies searching for employees.

DHI Group, Inc. (NYSE:DHX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.